ClinicalTrials.Veeva

Menu
F

Florida Retina Institute | Central Florida - Orlando

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Aflibercept
Faricimab
KSI-301
Ribociclib
APL 3007
Bevacizumab
MK-8748
BI 764524
ANX007
Pemafibrate

Parent organization

This site is a part of Florida Retina Institute

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

15 of 36 total trials

4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

A Phase 3, Randomized, Double-Masked, Active-Controlled Trial in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration

Active, not recruiting
Macular Neovascularization Secondary to Age-Related Macular Degeneration
Biological: 4D-150 IVT (3E10 vg/eye)
Biological: EYLEA® (aflibercept) Injection 2 mg (0.05mL)

This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.

Active, not recruiting
Wet Age Related Macular Degeneration
wAMD
Drug: Aflibercept (2.0 mg)
Drug: EYP-1901

Researchers are looking for new ways to treat neovascular age-related macular degeneration (NVAMD).Available standard (usual) treatments for NVAMD, s...

Enrolling
Choroidal Neovascularization
Age-Related Macular Degeneration
Drug: Tiespectus
Drug: Aflibercept

EYE-RES-104 is a randomized, dose-masked study of intravitreal EYE103 in participants with neovascular age-related macular degeneration (NVAMD) or ma...

Enrolling
Neovascular Age-Related Macular Degeneration (NVAMD)
Branch Retinal Vein Occlusion (BRVO)
Drug: EYE103
Drug: Aflibercept 2.0 mg

Investigate the Safety, Pharmacokinetics, and Treatment effects of Single and Multi-dose of Intravitreal AVD-104 in participants with geographic atro...

Active, not recruiting
Macular Degeneration
Geographic Atrophy of the Macula
Drug: AVD-104
Drug: Avacincaptad

A Phase 2, Randomized, Placebo-controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidos...

Enrolling
Geographic Atrophy Secondary to Age-related Macular Degeneration
Drug: APL-3007, pegcetacoplan (APL-2)
Other: Placebo, Syfovre

This study is researching aflibercept high dose (HD), referred to as "study drug", with an experimental dosing regimen. The study is focused on parti...

Active, not recruiting
Neovascular Age-Related Macular Degeneration
Diabetic Macular Edema
Drug: Aflibercept 8 mg

The primary purpose of the study is to determine if IVT injections of vonaprument every month reduce vision loss in participants with dry AMD with GA.

Active, not recruiting
Geographic Atrophy
Drug: Vonaprument
Other: Sham Administration

This study is a Phase IIIb/IV, multicenter, randomized, two-arm, open-label 100-week study to investigate the efficacy, safety, and durability of int...

Active, not recruiting
Neovascular Age-related Macular Degeneration (nAMD)
Drug: Faricimab

This study is designed to investigate treatment response in treatment-naïve underrepresented patients with diabetic macular edema (DME) who are treat...

Active, not recruiting
Diabetic Macular Edema
Drug: Faricimab

ABBV-RGX-314 (also known as RGX-314 and surabgene lomparvovec (sura-vec)) is being developed as a novel one-time gene therapy for the treatment of ne...

Active, not recruiting
Wet Age-related Macular Degeneration
WetAMD
Genetic: ABBV-RGX-314 Dose 1
Biological: Aflibercept (EYLEA®)

The goal of this clinical trial is to evaluate the efficacy, safety and pharmacokinetics of elamipretide in subjects with dry age-related macular deg...

Active, not recruiting
Age Related Macular Degeneration (ARMD)
Drug: Elamipretide
Drug: Placebo

A Phase 3, Randomized, Double-Masked, Active-Controlled Trial in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration

Enrolling
Neovascular Age-Related Macular Degeneration (nAMD)
Biological: 4D-150 IVT (3E10 vg/eye)
Biological: EYLEA® (aflibercept) Injection 2 mg (0.05mL)

The primary purpose of this study is to evaluate the safety and durability of single- and repeat administration of AR-14034 Sustained Release (SR) in...

Active, not recruiting
Neovascular Age-related Macular Degeneration (nAMD)
Drug: AR-14034 SR implant lower dose
Drug: Sham procedure
Locations recently updated

The purpose of this study is to collect efficacy and safety information of intravitreal injection for 3 experimental arms, including 2 dose levels of...

Enrolling
Age - Related Macular Degeneration (AMD)
Geographic Atrophy (GA)
Other: Sham
Drug: Avacincaptad Pegol intravitreal solution

Trial sponsors

Jaeb Center for Health Research logo
Kodiak Sciences logo
Novartis logo
4
Bayer logo
Boehringer Ingelheim logo
E
Roche logo
AbbVie logo
Alcon logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems